secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001558370-24-009567
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve increase in share reserve for 2006 Stock Incentive Plan to 17.5M shares
--------------------------------------------------------------------------------

- Seven directors elected; CEO Dror Bashan among those with over 22M for votes.
- Advisory vote on executive compensation passed: 17.0M for, 9.88M against.
- Stock plan amended: shares available increased from ~12.5M to 17,475,171.
- Kesselman & Kesselman (PwC Israel) ratified as auditor for fiscal 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/0001558370-24-009567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/plx-20240627x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer